Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

769 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The real impact of telaprevir dosage on the antiviral and side effects of telaprevir, pegylated interferon and ribavirin therapy for chronic hepatitis C patients with HCV genotype 1.
Oze T, Hiramatsu N, Yakushijin T, Yamada R, Harada N, Morishita N, Oshita M, Mita E, Ito T, Inui Y, Inada M, Tamura S, Yoshihara H, Imai Y, Kato M, Miyagi T, Yoshida Y, Tatsumi T, Kasahara A, Hayashi N, Takehara T. Oze T, et al. Among authors: inada m. J Viral Hepat. 2015 Mar;22(3):254-62. doi: 10.1111/jvh.12289. Epub 2014 Jul 31. J Viral Hepat. 2015. PMID: 25081140
Angiotensin II type 1 receptor-induced extracellular signal-regulated protein kinase activation is mediated by Ca2+/calmodulin-dependent transactivation of epidermal growth factor receptor.
Murasawa S, Mori Y, Nozawa Y, Gotoh N, Shibuya M, Masaki H, Maruyama K, Tsutsumi Y, Moriguchi Y, Shibazaki Y, Tanaka Y, Iwasaka T, Inada M, Matsubara H. Murasawa S, et al. Among authors: inada m. Circ Res. 1998 Jun 29;82(12):1338-48. doi: 10.1161/01.res.82.12.1338. Circ Res. 1998. PMID: 9648731
Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses.
Inoue Y, Hiramatsu N, Oze T, Yakushijin T, Mochizuki K, Hagiwara H, Oshita M, Mita E, Fukui H, Inada M, Tamura S, Yoshihara H, Hayashi E, Inoue A, Imai Y, Kato M, Miyagi T, Hohsui A, Ishida H, Kiso S, Kanto T, Kasahara A, Takehara T, Hayashi N. Inoue Y, et al. Among authors: inada m. J Viral Hepat. 2010 May;17(5):336-44. doi: 10.1111/j.1365-2893.2009.01182.x. Epub 2009 Aug 12. J Viral Hepat. 2010. PMID: 19678893
Long-term responders without eradication of hepatitis C virus after interferon therapy: characterization of clinical profiles and incidence of hepatocellular carcinoma.
Yabuuchi I, Imai Y, Kawata S, Tamura S, Noda S, Inada M, Maeda Y, Shirai Y, Fukuzaki T, Kaji I, Ishikawa H, Matsuda Y, Nishikawa M, Seki K, Matsuzawa Y. Yabuuchi I, et al. Among authors: inada m. Liver. 2000 Jul;20(4):290-5. doi: 10.1034/j.1600-0676.2000.020004290.x. Liver. 2000. PMID: 10959807
The importance of initial daily administration of interferon alpha for the eradication of hepatitis C virus in patients with chronic hepatitis C: a multicenter randomized trial.
Nakamura H, Ito H, Kimura Y, Takeda A, Ogawa H, Kanazawa S, Kuroda T, Inada M, Harada H, Kishimoto T, Zenda S, Terabayashi M, Saeki K, Wada M, Igarashi A, Uemiya M, Kobayashi Y, Hayashi E. Nakamura H, et al. Among authors: inada m. Hepatogastroenterology. 1998 Jul-Aug;45(22):1045-55. Hepatogastroenterology. 1998. PMID: 9756005 Clinical Trial.
769 results